pembrolizumab
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
Merck and Advaxis team up on immuno-oncology
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development ASCO, Merck, immunology, pd-1, pembrolizumab
Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …
PD-1 cancer race heats up as Merck takes lead
July 2, 2014Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab
Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
